You are here

Home » Industry » Prescription medicines » Regulatory decisions and notices » Australian Public Assessment Reports for prescription medicines (AusPARs)

AusPAR: Perampanel hemisesquihydrate

Related information

Australian Public Assessment Report

10 May 2021
AusPAR Details
AusPAR
AusPAR: Perampanel hemisesquihydrate (pdf, 3 MB)
AusPAR: Perampanel hemisesquihydrate (docx, 4 MB)
Attachment: Product Information: Perampanel hemisesquihydrate (pdf, 382 KB)
Attachment: Product Information: Perampanel hemisesquihydrate (docx, 103 KB)
Active Ingredient
Perampanel hemisesquihydrate
Product Name
Fycompa
Sponsor
Eisai Australia Pty Ltd
Submission Number
PM-2019-05359-1-1
Submission Type
Extension of indications
Decision
Approved
AusPAR Date
26 April 2021
Publication Date

10 May 2021